⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Tubeimoside I (TBMS1)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-15 — Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.: Preclinical senolytic identification: TBMS1 selectively killed senescent cells in vitro by binding ATP1A1 (Na+/K+ ATPase α1) and disrupting K+/ion homeostasis, driving mitochondrial dysfunction and apoptosis; in radiation-induced and naturally aged mice it reduced senescence markers and improved motor function without overt toxicity — establishes a mechanistically distinct senolytic axis (ATP1A1 / ion homeostasis) versus BCL-2 family or flavonoid senolytics. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.
15-apr-2026
novelty 3
per-area 3
strengthens